Vivani Medical, Inc. (VANI) Key Metrics
VANI valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $101.0M
- Enterprise value
- $108.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 5.8 10-yr median 4.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 3.30
VANI key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsVANI valuation Price multiples at each fiscal year-end price.
VANI returns How much profit the business earns on the capital it uses.
VANI per-share figures Results divided by the shares outstanding at year-end.
VANI financial health Debt, liquidity and how easily interest is covered.
VANI efficiency & capital use Working capital cycle and where the cash goes.
VANI valuation history
VANI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VANI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VANI cash returned to shareholders
VANI price vs earnings per share
VANI key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $76.7M | $63.8M | $51.9M | $32.5M | $177.3M | $157.7M | — | — | — | — |
| Enterprise value | $79.4M | $64.7M | $51.9M | −$11.6M | $176.9M | $158.1M | — | — | — | — |
| Price / book | 4.9 | 3.6 | 2.5 | 0.7 | 71.9 | 80.9 | — | — | — | — |
| Earnings yield | −34.7% | −36.8% | −49.5% | −42.7% | −7.2% | −5.9% | — | — | — | — |
| Free cash flow yield | −33.2% | −33.5% | −47.4% | −58.8% | −5.2% | −4.9% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — | — | 0.2% | — | — | — | — |
| Share price at fiscal year-end | $1.23 | $1.16 | $1.02 | $0.85 | $4.89 | $5.61 | $17.81 | $21.26 | $45.84 | $47.28 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Earnings per share | −$0.43 | −$0.43 | −$0.50 | −$0.36 | −$0.35 | −$0.33 | — | — | — | — |
| Operating cash flow per share | −$0.39 | −$0.38 | −$0.47 | −$0.49 | −$0.25 | −$0.27 | — | — | — | — |
| Free cash flow per share | −$0.41 | −$0.39 | −$0.48 | −$0.50 | −$0.25 | −$0.28 | — | — | — | — |
| Cash per share | $0.26 | $0.33 | $0.41 | $1.18 | $0.06 | $0.07 | — | — | — | — |
| Book value per share | $0.25 | $0.32 | $0.41 | $1.16 | $0.07 | $0.07 | — | — | — | — |
| Tangible book value per share | $0.25 | $0.32 | $0.41 | $1.16 | $0.07 | $0.07 | — | — | — | — |
| Capex per share | $0.02 | $0.01 | $0.02 | $0.01 | $0.00 | $0.01 | — | — | — | — |
| Debt per share | $0.30 | $0.35 | $0.41 | $0.02 | $0.05 | $0.09 | — | — | — | — |
| Shares outstanding | 62.4M | 55.0M | 50.9M | 38.2M | 36.3M | 28.1M | — | — | — | — |
| Change in shares outstanding | +13.5% | +8.1% | +33.0% | +5.5% | +29.0% | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −159.6% | −122.4% | −78.8% | −59.4% | −578.6% | −201.2% | −648.6% | −640.1% | −299.7% | −211.2% |
| Return on invested capital (ROIC) | −117.9% | −99.0% | −203.0% | — | −474.6% | — | — | — | — | — |
| Return on assets (ROA) | −65.7% | −53.8% | −52.9% | −49.1% | −239.4% | −85.1% | −246.3% | −278.8% | −182.2% | −147.3% |
| Return on tangible assets | −67.5% | −56.5% | −56.0% | −27.2% | −234.2% | −177.9% | −202.4% | −328.5% | −196.7% | −197.4% |
| Free cash flow margin | — | — | — | — | — | — | −832.3% | −434.6% | −304.0% | −641.4% |
| Financial health | ||||||||||
| Total debt | $18.9M | $19.3M | $20.7M | $955,000 | $1.8M | $2.5M | $2.6M | — | — | — |
| Cash & short-term investments | $16.2M | $18.4M | $20.7M | $45.1M | $2.2M | $2.1M | $11.3M | $4.5M | $7.8M | $10.9M |
| Net debt | $2.6M | $961,000 | $42,000 | −$44.1M | −$366,000 | $386,000 | −$8.7M | −$4.5M | −$7.8M | −$10.9M |
| Debt / equity | 1.20 | 1.10 | 1.00 | 0.02 | 0.74 | 1.27 | 0.36 | — | — | — |
| Debt / assets | 0.48 | 0.46 | 0.45 | 0.02 | 0.33 | 0.47 | 0.16 | — | — | — |
| Current ratio | 2.71 | 3.41 | 4.03 | 6.97 | 1.18 | 1.11 | 1.88 | 1.27 | 1.99 | 2.70 |
| Quick ratio | 2.71 | 3.41 | 4.03 | 6.97 | 1.18 | 1.11 | 1.74 | 0.84 | 1.58 | 2.10 |
| Interest coverage | — | — | — | -2.9 | -24.2 | — | — | — | — | — |
| Working capital | $11.3M | $14.5M | $17.3M | $40.7M | $383,000 | $244,000 | $6.2M | $2.0M | $6.5M | $9.6M |
| Invested capital | $18.4M | $18.6M | $20.8M | $187,000 | $2.1M | $2.3M | −$1.4M | −$1.4M | $43,000 | $275,000 |
| Tangible asset value | $15.7M | $17.6M | $20.8M | $44.3M | $2.5M | $1.9M | $7.3M | $3.1M | $7.9M | $11.2M |
| Net current asset value | −$5.8M | −$3.5M | −$2.0M | $40.7M | −$519,000 | −$838,000 | $3.8M | $2.0M | $6.5M | $9.6M |
| Graham net-net per share | −$0.11 | −$0.10 | −$0.09 | $1.00 | −$0.02 | −$0.04 | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | $28,000 | — | — | — | — | $281,000 | — | — | — | — |
| Capex / revenue | — | — | — | — | 5,384.6% | 15,000.0% | 14.6% | 2.4% | 3.3% | 12.3% |
| Capex / depreciation | 2.77 | 1.39 | 2.48 | 0.89 | 0.20 | 0.42 | 1.19 | 0.37 | 0.58 | 1.13 |
| Stock-based compensation / revenue | — | — | — | — | 28,846.2% | 103,700.0% | 86.6% | 52.0% | 47.5% | 84.5% |
| R&D / revenue | — | — | — | — | 4,231,538.5% | 686,500.0% | 488.2% | 148.0% | 100.4% | 134.2% |
| SG&A / revenue | — | — | — | — | 892,692.3% | 237,800.0% | 453.6% | 319.4% | 257.4% | 478.5% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | 51.8 | 61.8 | 48.2 | 81.3 |
| Days of inventory on hand | — | — | — | — | — | — | 362.9 | 222.2 | 144.0 | 226.9 |
| Days payables outstanding | 795.9 | 620.0 | 878.8 | 698.4 | 266.6 | 1,438.1 | 203.4 | 76.8 | 44.9 | 36.4 |
| Cash conversion cycle (days) | — | — | — | — | — | — | 211.3 | 207.1 | 147.3 | 271.8 |
| Receivables turnover | 0.00 | 0.00 | — | — | — | — | 7.05 | 5.91 | 7.57 | 4.49 |
| Payables turnover | 0.46 | 0.59 | 0.42 | 0.52 | 1.37 | 0.25 | 1.79 | 4.75 | 8.13 | 10.02 |
| Inventory turnover | — | — | — | — | — | — | 1.01 | 1.64 | 2.54 | 1.61 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.55 | 0.51 | 0.18 |
| Average receivables | $453,500 | $253,000 | — | — | — | — | $479,500 | $1.2M | $1.1M | $887,500 |
| Average payables | $924,500 | $679,500 | $859,500 | $729,000 | $252,000 | $658,000 | $1.2M | $1.0M | $954,000 | $933,000 |
| Average inventory | — | — | — | — | — | — | $2.1M | $3.0M | $3.1M | $5.8M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from VANI's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VANI valuation and financial ratios
Vivani Medical earned a return on equity of −159.6% and a return on invested capital of −117.9% in fiscal 2025. It ended the year with $18.9 million of debt and $16.2 million in cash and short-term investments, net debt of $2.6 million. It returned $0.0 million to shareholders: $0 in dividends and $0.0 million in share buybacks.
See the VANI income statement, the VANI chart for price history, or the VANI stock overview for the latest quote and news.
VANI key metrics FAQ
What is Vivani Medical's return on equity?
Vivani Medical's return on equity (ROE) was −159.6% in fiscal 2025: net income of -$26.6 million on average shareholders' equity of $16.7 million.
What is Vivani Medical's ROIC?
Vivani Medical's return on invested capital was −117.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Vivani Medical have?
Vivani Medical had total debt of $18.9 million at the end of fiscal 2025, a debt-to-equity ratio of 1.20.
Does Vivani Medical buy back its shares?
Yes. Vivani Medical spent $0.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +13.5% over the year, to 62.4M..
What is Vivani Medical's free cash flow yield?
Vivani Medical generated -$25.5 million of free cash flow in fiscal 2025, a free cash flow yield of −33.2% on its market value at year-end ($76.7 million).
What is Vivani Medical's current ratio?
Vivani Medical's current ratio was 2.71 at the end of fiscal 2025: current assets were 2.71 times current liabilities.